Past Tuesday Talks: The Research Reproducibility Problem and its Impact on Drug Discovery

Tuesday, January 24th, 2023

Presented by Seema Kumar, CEO, Cure

“…for most study designs and settings, it is more likely for a research claim to be false than true.” – John Ioannidis, physician and researcher, Stanford, in PloS

It’s widely known that the results in at least half of all life published science studies cannot be reproduced when researchers try to verify results. What’s less known is what happens when potential therapeutics move from the lab to companies looking to develop new drugs and treatments. Christine Brideau is well-acquainted with this verification gap from her work at the fulcrum of turning basic research into products working at Deerfield and previously at WuXi and Merck. Join us on January 24 as she describes recent studies on reproducibility from the likes of Bayer and Amgen, and also shares her own experience and insights—and offers suggestions for how to narrow the verification gap.

Tuesday Talks: The Research Reproducibility Problem and its Impact on Drug Discovery

When: Tuesday, January 24, 4:30 pm – 6:30 pm
Where: Rooftop at Cure. 345 Park Avenue South, New York, NY 10010

Topic: A fireside chat on recent studies on reproducibility from the likes of Bayer and Amgen and Christine’s own experience, insights and suggestions for how to narrow the verification gap.
Speakers: Christine Brideau, Vice President, Preclinical Pharmacology, Deerfield Discovery and Development. Moderated by Seema Kumar, CEO of Cure

Featured Speakers

About Seema Kumar

Ms. Kumar joins Cure from Johnson & Johnson where she spent nearly 20 years in senior leadership positions, most recently serving as Global Head of the Office of Innovation, Global Health and Scientific Engagement. During her tenure, she led the launch of the company’s Innovation Centers, JLABS and Global Public Health initiatives, as well as the CoLaboratory at the World Economic Forum at Davos and the award winning COVID-19 educational broadcast program, “The Road to a Vaccine.”

About Christine Brideau

Christine Brideau is a Vice President, Preclinical Pharmacology, Deerfield Discovery and Development, and joined the Firm in 2019. Prior to Deerfield, Ms. Brideau was Vice President of In Vitro Pharmacology at WuXi AppTec and led the development of WuXi’s US-based in vitro biology unit in New Jersey. Before WuXi, Ms. Brideau spent 24 years at Merck, where she most recently served as Executive Director of In Vitro Pharmacology and supported multiple drug discovery projects from hit-to-lead to clinical candidate. She is the co-author of more than 40 peer-reviewed publications in the areas of pharmacology, assay development, screening day analysis, automation and compound management. Ms. Brideau is currently an editorial board member of SLAS Discovery and has served as a reviewer for the NIH Molecular Libraries Program study section.